Sign in
Taking people in United StatesNo phase

Treating sleep apnea in veterans with substance use disorder and PTSD in residential care

Tests airway pressure treatment for sleep apnea in veterans with substance use disorder and PTSD.

Key facts

Who runs it
VA Office of Research and Development
Where
San Diego, United StatesSee the site
Trial code
Registry title
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Status
Recruiting
People taking part
194 people, planned
Started
2 Jan 2023
Expected to end
31 May 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Positive Airway Pressure Device
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for U.S. Veterans with obstructive sleep apnea, substance use disorder and PTSD who are on a residential treatment unit. It compares sleep apnea treatment with a breathing device (PAP) on the unit to a waitlist group.

Age
18 Years and older
Sex
All sexes
Disease stage
Obstructive sleep apnea with an Apnea Hypopnea Index (AHI) of 5 per hour. Current substance use disorder with at least 20 days of substance use in the last 90 days. Full PTSD diagnosis, with trauma at least one month ago. Must be on the PTSD track of the Substance Abuse Residential Rehabilitation Treatment Program (SARRPT) unit.
Earlier treatment
People who already use a positive airway pressure (PAP) device when they arrive cannot join. People diagnosed with OSA before but not using PAP can join.
Biomarker or test result
Apnea Hypopnea Index (AHI) 5 per hour on a sleep test.

Main reasons for not taking part

  • Central sleep apnea (AHI>=5 and > 50% central apneas)
  • Already using a PAP device on arrival
  • Unit medical staff advise against joining
  • Severe memory or thinking problems (MOCA < 26)
  • History of psychosis or mania not caused by substance use

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • a Veteran of the U.S. military or Reserve/National Guard member
  • have an Apnea Hypopnea Index (AHI) 5 per hour
  • experienced trauma that occurred in childhood or adulthood; at least one month post-trauma
  • have current DSM-5 diagnoses of substance use disorder (SUD) via Structured Clinical Interview for DSM-Substance Use Disorders (SCID-SUD) module with a minimum 20 days of substance use in the last 90 days (Timeline Follow-back)
  • Full post-traumatic stress disorder (PTSD) diagnosis via clinician administered post-traumatic stress disorder (PTSD) scale
  • are literate in English
  • are on the post-traumatic stress disorder (PTSD) track of the Substance Abuse Residential Rehabilitation Treatment Program (SARRPT) unit
  • are capable of giving informed consent

Who cannot take part

  • arrives on the Substance Abuse Residential Rehabilitation Treatment Program (SARRPT) unit already using a positive airway pressure (PAP) device (Veteran's previously diagnosed with OSA, but not using positive airway pressure (PAP) therapy will be eligible)
  • the Substance Abuse Residential Rehabilitation Treatment Program (SARRPT) medical staff advises against the study based on medical history and physical examination; d) history of severe cognitive impairment (via Montreal Cognitive Assessment (MOCA) < 26)
  • history of psychosis or mania independent of substance use will be excluded because the presence of these disorders can impede therapy progress
  • have central sleep apnea (Apnea Hypopnea Index (AHI)>=5 and > 50% central apneas)

Where in United States

  • VA San Diego Healthcare System, San Diego, CASan Diego, United StatesContact: Peter Colvonen, PhDTaking people

About the trial

What the trial wants to find out

Substance use disorder (SUD) and posttraumatic stress disorder (PTSD) frequently co-occur and having both disorders is associated with greater psychological and functional impairment than having either disorder alone. This is especially true in residential settings where both disorders are more severe than outpatient settings. Obstructive sleep apnea (OSA) is highly comorbid with both disorders and untreated OSA is associated with worse functional impairment across multiple domains, worse quality of life, worse PTSD, higher suicidal ideation, and higher substance use and relapse rates. Treating OSA with evidence-based positive airway pressure (PAP) in Veterans with SUD/PTSD on a residential unit is a logical way to maximize treatment adherence and treatment outcomes. This study compares OSA treatment while on a SUD/PTSD residential unit to a waitlist control group. The investigators hypothesize that treating OSA on the residential unit, compared to the waitlist control, will have better functional, SUD, and PTSD outcomes.

The 2 groups in the trial

  • PAP Treatment on SARRTP UnitTreatment being tested

    Veterans will receive Positive Airway Pressure device while on the 28-day SARRTP Unit.

    Treatment: Positive Airway Pressure Device

  • Waitlist ControlNo study treatment, for comparison

    Veterans will not receive PAP device until after 3-month Follow Up.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Examining Early Intervention Obstructive Sleep Apnea Treatment on Long-Term Outcomes in Veterans With SUD/PTSD in a Residential Treatment Program
Plain-language title
Treating sleep apnea in veterans with substance use disorder and PTSD in residential careGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
19 October 2026